Literature DB >> 15124689

PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.

R M Stone1, J De Angelo, I Galinsky, E Estey, V Klimek, W Grandin, D Lebwohl, A Yap, P Cohen, E Fox, D Neuberg, J Clark, D G Gilliland, J D Griffin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15124689     DOI： 10.1007/s00277-004-0850-2

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  14 in total

1.  Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.

Authors:  Talha Badar; Hagop M Kantarjian; Graciela M Nogueras-Gonzalez; Gautam Borthakur; Guillermo Garcia Manero; Michael Andreeff; Marina Konopleva; Tapan M Kadia; Naval Daver; William G Wierda; Raja Luthra; Keyur Patel; Betul Oran; Richard Champlin; Farhad Ravandi; Jorge E Cortes
Journal:  Am J Hematol       Date:  2015-09-10       Impact factor: 10.047

2.  A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia.

Authors:  Daniel J Deangelo; Donna Neuberg; Philip C Amrein; Jacob Berchuck; Martha Wadleigh; L Andres Sirulnik; Ilene Galinsky; Todd Golub; Kimberly Stegmaier; Richard M Stone
Journal:  Leuk Res       Date:  2013-11-05       Impact factor: 3.156

3.  Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.

Authors:  Ellen Weisberg; Johannes Roesel; Guido Bold; Pascal Furet; Jingrui Jiang; Jan Cools; Renee D Wright; Erik Nelson; Rosemary Barrett; Arghya Ray; Daisy Moreno; Elizabeth Hall-Meyers; Richard Stone; Ilene Galinsky; Edward Fox; Gary Gilliland; John F Daley; Suzan Lazo-Kallanian; Andrew L Kung; James D Griffin
Journal:  Blood       Date:  2008-09-26       Impact factor: 22.113

4.  Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.

Authors:  Ellen Weisberg; Lolita Banerji; Renee D Wright; Rosemary Barrett; Arghya Ray; Daisy Moreno; Laurence Catley; Jingrui Jiang; Elizabeth Hall-Meyers; Maira Sauveur-Michel; Richard Stone; Ilene Galinsky; Edward Fox; Andrew L Kung; James D Griffin
Journal:  Blood       Date:  2008-01-09       Impact factor: 22.113

Review 5.  FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.

Authors:  Ellen Weisberg; Rosemary Barrett; Qingsong Liu; Richard Stone; Nathanael Gray; James D Griffin
Journal:  Drug Resist Updat       Date:  2009-05-20       Impact factor: 18.500

6.  Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα.

Authors:  Hanna S Radomska; Meritxell Alberich-Jordà; Britta Will; David Gonzalez; Ruud Delwel; Daniel G Tenen
Journal:  J Clin Invest       Date:  2012-07-17       Impact factor: 14.808

7.  Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells.

Authors:  Ellen Weisberg; Arghya Ray; Erik Nelson; Sophia Adamia; Rosemary Barrett; Martin Sattler; Chengsheng Zhang; John F Daley; David Frank; Edward Fox; James D Griffin
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

8.  Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.

Authors:  Hanna S Radomska; Daniela S Bassères; Rui Zheng; Pu Zhang; Tajhal Dayaram; Yukiya Yamamoto; David W Sternberg; Nathalie Lokker; Neill A Giese; Stefan K Bohlander; Susanne Schnittger; Marie-Hélène Delmotte; Roger J Davis; Donald Small; Wolfgang Hiddemann; D Gary Gilliland; Daniel G Tenen
Journal:  J Exp Med       Date:  2006-01-30       Impact factor: 14.307

9.  Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis.

Authors:  Mamdooh Gari; Adel Abuzenadah; Adeel Chaudhary; Mohammed Al-Qahtani; Huda Banni; Waseem Ahmad; Fatin Al-Sayes; Sahira Lary; Ghazi Damanhouri
Journal:  Int J Mol Sci       Date:  2008-11-11       Impact factor: 6.208

10.  Smac mimetics: implications for enhancement of targeted therapies in leukemia.

Authors:  E Weisberg; A Ray; R Barrett; E Nelson; A L Christie; D Porter; C Straub; L Zawel; J F Daley; S Lazo-Kallanian; R Stone; I Galinsky; D Frank; A L Kung; J D Griffin
Journal:  Leukemia       Date:  2010-09-16       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.